Equities analysts expect American Renal Associates Holdings, Inc (NYSE:ARA) to report $0.16 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for American Renal Associates Holdings’ earnings. The highest EPS estimate is $0.17 and the lowest is $0.15. American Renal Associates Holdings reported earnings of $0.28 per share during the same quarter last year, which suggests a negative year-over-year growth rate of 42.9%. The firm is expected to issue its next earnings results on Thursday, November 9th.

On average, analysts expect that American Renal Associates Holdings will report full-year earnings of $0.54 per share for the current year, with EPS estimates ranging from $0.50 to $0.58. For the next fiscal year, analysts anticipate that the company will report earnings of $0.71 per share, with EPS estimates ranging from $0.70 to $0.72. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow American Renal Associates Holdings.

American Renal Associates Holdings (NYSE:ARA) last posted its quarterly earnings results on Tuesday, August 8th. The company reported $0.16 EPS for the quarter, beating the Zacks’ consensus estimate of $0.12 by $0.04. American Renal Associates Holdings had a negative net margin of 1.54% and a positive return on equity of 18.25%. The company had revenue of $185.99 million during the quarter, compared to analyst estimates of $188.23 million. American Renal Associates Holdings’s quarterly revenue was up .2% compared to the same quarter last year.

Several analysts have recently weighed in on ARA shares. Zacks Investment Research upgraded American Renal Associates Holdings from a “sell” rating to a “hold” rating in a research report on Wednesday, May 10th. Wells Fargo & Company upgraded American Renal Associates Holdings from a “market perform” rating to an “outperform” rating in a research report on Thursday, May 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. American Renal Associates Holdings presently has a consensus rating of “Hold” and a consensus target price of $22.33.

Shares of American Renal Associates Holdings (NYSE ARA) opened at 14.33 on Monday. The company’s market capitalization is $448.31 million. American Renal Associates Holdings has a 12-month low of $13.48 and a 12-month high of $25.42. The company’s 50-day moving average is $15.72 and its 200-day moving average is $17.53.

TRADEMARK VIOLATION NOTICE: “Zacks: Brokerages Anticipate American Renal Associates Holdings, Inc (ARA) to Announce $0.16 Earnings Per Share” was originally reported by Daily Political and is owned by of Daily Political. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.dailypolitical.com/2017/09/04/zacks-brokerages-anticipate-american-renal-associates-holdings-inc-ara-to-announce-0-16-earnings-per-share.html.

Several large investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company lifted its position in shares of American Renal Associates Holdings by 19.7% during the second quarter. The Manufacturers Life Insurance Company now owns 8,778 shares of the company’s stock worth $162,000 after purchasing an additional 1,443 shares during the last quarter. State Street Corp lifted its position in shares of American Renal Associates Holdings by 5.2% during the second quarter. State Street Corp now owns 146,039 shares of the company’s stock worth $2,709,000 after purchasing an additional 7,244 shares during the last quarter. Dimensional Fund Advisors LP bought a new stake in shares of American Renal Associates Holdings during the second quarter worth $230,000. Vanguard Group Inc. lifted its position in shares of American Renal Associates Holdings by 7.9% during the second quarter. Vanguard Group Inc. now owns 1,002,294 shares of the company’s stock worth $18,593,000 after purchasing an additional 73,526 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of American Renal Associates Holdings by 33.4% during the second quarter. Northern Trust Corp now owns 143,693 shares of the company’s stock worth $2,666,000 after purchasing an additional 35,965 shares during the last quarter. Institutional investors and hedge funds own 89.92% of the company’s stock.

About American Renal Associates Holdings

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

Get a free copy of the Zacks research report on American Renal Associates Holdings (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for American Renal Associates Holdings (NYSE:ARA)

Receive News & Ratings for American Renal Associates Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.